Novartis Ag (NVS) EPS (Basic) Growth (3y) (2012 - 2026)
Novartis Ag (NVS) EPS (Basic) Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.37 Bn | 632.61 Bn | 17.26 Bn | 5.11% |
| 2 | AbbVie | 469.65 Bn | 463.08 Bn | 12.70 Bn | 21.23% |
| 3 | Merck | 376.13 Bn | 368.99 Bn | 12.21 Bn | 38.72% |
| 4 | Novartis Ag | 303.28 Bn | 295.59 Bn | 11.24 Bn | -59.02% |
| 5 | Astrazeneca | 258.06 Bn | 253.16 Bn | 12.86 Bn | 11.28% |
| 6 | Amgen | 236.35 Bn | 222.36 Bn | 7.24 Bn | 19.50% |
| 7 | Gilead Sciences | 182.15 Bn | 178.97 Bn | 6.22 Bn | -129.90% |
| 8 | Pfizer | 159.57 Bn | 147.87 Bn | 10.94 Bn | -28.08% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -34.06% |
| 10 | Sanofi | 55.20 Bn | 47.82 Bn | 10.79 Bn | -35.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -59.02% |
| Jun 30, 2025 | -9.03% |
| Dec 31, 2024 | -10.22% |
| Jun 30, 2024 | -5.20% |
| Dec 31, 2023 | -3.31% |
| Sep 30, 2023 | -97.52% |
| Jun 30, 2023 | 1.92% |
| Mar 31, 2023 | -7.96% |
| Dec 31, 2022 | 3.96% |
| Sep 30, 2022 | 27.17% |
| Jun 30, 2022 | 8.74% |
| Mar 31, 2022 | 4,030.05% |
| Dec 31, 2021 | -3.82% |
| Sep 30, 2021 | 96.83% |
| Jun 30, 2021 | -9.96% |
| Mar 31, 2021 | 10,252.93% |
| Dec 31, 2020 | -7.70% |
| Sep 30, 2020 | 2,049.51% |
| Jun 30, 2020 | 203.48% |
| Mar 31, 2020 | -50.88% |